Through our pipeline, policies, and advocacy efforts, we seek to protect the benefits of antibiotics in human medicine, while responsibly protecting the health of farm animals and the safety of our food supply. Elanco has intentionally shifted our business away from shared-class antibiotics – those used in both humans and animals. We've removed growth promotion from nearly 100 product labels globally and removed over-the-counter use from nearly 70 product labels to require the oversight of a veterinarian. Most importantly, Elanco has focused on expanding access to animal-only antibiotics, which don’t create a threat to human resistance, and creating antibiotic alternatives, including vaccines, enzymes, probiotics and prebiotics. For example, Elanco’s work in vaccines, particularly salmonella, directly reduces exposure to pathogens in people, ultimately reducing the need for antibiotics in both animals and people.
By 2030, Elanco will seek to:
- Invest more than $3.5B in innovation to pursue the discovery and development of products that improve the health and care of animals, including products that would reduce the need for medically important antibiotics.
- Expand the availability of vaccines, nutritional health products, and diagnostics in underserved markets that currently rely on medically important antibiotics.
- Increase access to innovation, knowledge, and partnerships for small-holder farmers by adapting the value-chain to ensure the responsible use of antibiotics.
- Expand engagement with stakeholders, solicit concerns and expectations of responsible antibiotic use and the responsible care of antibiotics.
Our Antibiotic Stewardship Principals
Elanco is committed to continuing our antibiotic stewardship programs, visit our antibiotic stewardship principals for more details.